CTIS2022-501697-19-00进行中（未招募）1 期
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) - MK-1026-011
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 993
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to have a need to initiate therapy., Has at least 1 marker of disease burden., Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization., Has the ability to swallow and retain oral medication., Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization., Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening., Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.
排除标准
- •Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection., Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors., Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids., Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed., Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration., Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication., Has active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed., Has active infection requiring systemic therapy., Participants who have not adequately recovered from major surgery or have ongoing surgical complications., Has gastrointestinal (GI) dysfunction that may affect drug absorption., Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL., Has had acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening., Has QT interval corrected (QTc) prolongation or other significant electrocardiogram (ECG) abnormalities., Has hypersensitivity to nemtabrutinib or contraindication to ibrutinib or acalabrutinib, or any of the excipients., Has history of severe bleeding disorder., Has history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years., Has received any systemic anticancer therapy for CLL/SLL.
研究者
相似试验
招募中
1 期
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE 011)Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)MedDRA version: 21.0Level: LLTClassification code: 10051812Term: Small cell lymphocytic lymphoma Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10024340Term: Leukemia lymphocytic chronic Class: 10029104CTIS2022-501697-19-01Merck Sharp & Dohme LLC1,288
尚未招募
3 期
A Phase 3 Study of Nemtabrutinib vs Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) for 1L CLL/SC911 Chronic lymphocytic leukaemia of B-cell typeChronic lymphocytic leukaemia of B-cell typeC911PER-046-23Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)
招募中
3 期
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Small Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT06136559Merck Sharp & Dohme LLC1,200
进行中（未招募）
1 期
A Phase 1 clinical study of nemtabrutinib in Japanese participants with hematological malignanciesmature B-cell neoplasmsJPRN-jRCT2031220583Koh Yasuhiro12
未知
3 期
A phase III, double-blind, comparative study of NE-58095 (once-monthly formulation)Involutional osteoporosisJPRN-jRCT2080220994Ajinomoto Pharmaceuticals Co., Ltd.